Protara Therapeutics, Inc. (TARA) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Available-for-sale Securities, Current |
| Current obligations | 13.32M USD | Liabilities, Current |
| Cash and equivalents | 17.08M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 125.42M USD | Marketable Securities, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $13.32M | $17.08M | $125.42M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $8.92M | $14.74M | $121.05M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $10.94M | $49.66M | $105.90M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $9.91M | $12.55M | $120.12M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $9.76M | $31.50M | $90.72M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $7.02M | $91.46M | $32.90M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $10.96M | $162.80M | $7.49M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $8.64M | $51.76M | $29.74M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $5.65M | $89.58M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $5.50M | $52.23M | $2.99M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $6.15M | $39.59M | $25.99M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $6.78M | $33.77M | $40.27M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $4.93M | $33.98M | $46.38M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $6.41M | $21.04M | $65.58M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $5.74M | $24.13M | $60.24M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $3.71M | $47.50M | $48.82M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $3.49M | $33.81M | $64.64M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $2.86M | $25.44M | $62.16M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $4.30M | $35.72M | $55.51M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $3.69M | $40.74M | $53.02M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $3.67M | $46.84M | $37.83M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $3.31M | $58.20M | $26.14M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $2.92M | $168.60M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $3.89M | $165.90M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $3.45M | $29.97M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $4.97M | $36.07M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $583.00K | $6.18M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $1.61M | $9.35M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $2.12M | $10.81M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $3.37M | $16.76M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $3.08M | $19.37M | $2.50M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $2.53M | $18.23M | $7.99M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $2.23M | $12.48M | $13.97M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $9.02M | $25.36M | $11.46M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $9.24M | $21.17M | $20.97M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $9.09M | $19.99M | $27.44M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $4.14M | $18.39M | $13.36M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $3.02M | $34.13M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $5.08M | $36.39M | $4.92M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $4.94M | $26.68M | $20.30M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $4.74M | $34.19M | $19.49M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $3.59M | $24.06M | $35.33M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $4.13M | $40.03M | $25.23M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $3.17M | $35.98M | $34.56M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $2.77M | $16.82M | $57.92M | (m) | (m) | (m) |
| 2015-03-31 | (m) | $2.63M | $9.78M | $69.74M | (m) | (m) | (m) |
| 2014-12-31 | (m) | $2.34M | $68.84M | $14.76M | (m) | (m) | (m) |
| 2014-09-30 | (m) | $2.66M | $3.24M | $18.45M | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $8.65M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $3.59M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $9.77M | $2.79M | $2.36M | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | $6.86M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $2.41M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $3.27M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |